The Latest in Critical Care, 10/30/23 (Issue #18)

Societies call for SEP-1 elimination; Amikacin for VAP (AMIKINHAL trial); Statins for Covid-19 pneumonia (REMAP-CAP trial)

Oct 30, 2023

∙ Paid

Professional Medical Societies Call for Elimination of SEP-1

Apr 30

The Infectious Diseases Society of America (IDSA), along with societies for emergency medicine physicians and hospitalists, are again speaking up about the ongoing policy experiment known as the Centers for Medicare and Medicaid Severe Sepsis/Septic Shock Management Bundle (SEP-1).

Read full story

Amikacin for Ventilator-Associated Pneumonia (AMIKINHAL trial)

PulmCCM

Apr 30

Amikacin for Ventilator-Associated Pneumonia (AMIKINHAL trial)

You don’t hear much about ventilator-associated pneumonia (VAP) anymore. It used to be highly prevalent in U.S. ICUs, and a popular research focus for academics, generating a steady stream of papers. Then, in 2009, the condition disappeared completely.

Read full story

Simvastatin for Covid-19 Pneumonia (REMAP-CAP trial)

PulmCCM

Apr 30

Simvastatin has anti-inflammatory properties, and while it isn’t an effective treatment for ARDS overall, it may improve outcomes in the subset of people with ARDS due to increased inflammation. Observationally, patients who contracted Covid-19 pneumonia in the Wuhan and Delta eras while taking statins tended to have better outcomes than those not taking statins. The REMAP-CAP randomized trial began enrolling in October 2020 to test statins’ effects in people with Covid-19, which at that time was producing a hyperinflammatory form of ARDS.

Read full story

Keep reading with a 7-day free trial

Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.